| Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study PK Bendapudi, S Hurwitz, A Fry, MB Marques, SW Waldo, A Li, L Sun, ... The Lancet Haematology 4 (4), e157-e164, 2017 | 505 | 2017 |
| Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3‐ITD acute myeloid leukaemia in first complete remission AM Brunner, S Li, AT Fathi, M Wadleigh, VT Ho, K Collier, C Connolly, ... British journal of haematology 175 (3), 496-504, 2016 | 208 | 2016 |
| Development and validation of a novel acute myeloid leukemia–composite model to estimate risks of mortality ML Sorror, BE Storer, AT Fathi, AT Gerds, BC Medeiros, P Shami, ... JAMA oncology 3 (12), 1675-1682, 2017 | 176 | 2017 |
| Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: a randomized clinical trial A El-Jawahri, TW LeBlanc, A Kavanaugh, JA Webb, VA Jackson, ... JAMA oncology 7 (2), 238-245, 2021 | 146 | 2021 |
| Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort M Stahl, M DeVeaux, P Montesinos, R Itzykson, EK Ritchie, MA Sekeres, ... Blood advances 2 (8), 923-932, 2018 | 145 | 2018 |
| Health care utilization and end‐of‐life care for older patients with acute myeloid leukemia AR El‐Jawahri, GA Abel, DP Steensma, TW LeBlanc, AT Fathi, ... Cancer 121 (16), 2840-2848, 2015 | 144 | 2015 |
| Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Leukemia 35 (12), 3542-3550, 2021 | 141 | 2021 |
| The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort M Stahl, M DeVeaux, T De Witte, J Neukirchen, MA Sekeres, AM Brunner, ... Blood advances 2 (14), 1765-1772, 2018 | 136 | 2018 |
| NCCN Guidelines® insights: myelodysplastic syndromes, version 3.2022: featured updates to the NCCN guidelines PL Greenberg, RM Stone, A Al-Kali, JM Bennett, U Borate, AM Brunner, ... Journal of the National Comprehensive Cancer Network 20 (2), 106-117, 2022 | 106 | 2022 |
| Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis M Movassaghian, AM Brunner, TM Blonquist, H Sadrzadeh, A Bhatia, ... Leukemia & lymphoma 56 (6), 1698-1703, 2015 | 106 | 2015 |
| Results of a clinical trial of H3B-8800, a splicing modulator, in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia … DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Blood 134, 673, 2019 | 104 | 2019 |
| Trends in all‐cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis AM Brunner, F Campigotto, H Sadrzadeh, BJ Drapkin, YB Chen, ... Cancer 119 (14), 2620-2629, 2013 | 104 | 2013 |
| Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark J Taylor, M Haddadin, VA Upadhyay, E Grussie, N Mehta-Shah, ... Blood, The Journal of the American Society of Hematology 134 (8), 678-687, 2019 | 97 | 2019 |
| Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS … AM Brunner, J Esteve, K Porkka, S Knapper, E Traer, S Scholl, ... Blood 138, 244, 2021 | 96 | 2021 |
| Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Blood 134, 570, 2019 | 91 | 2019 |
| High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML SS Patel, FC Kuo, CJ Gibson, DP Steensma, RJ Soiffer, EP Alyea III, ... Blood, The Journal of the American Society of Hematology 131 (25), 2816-2825, 2018 | 91 | 2018 |
| Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia AM Brunner, H Sadrzadeh, Y Feng, BJ Drapkin, KK Ballen, EC Attar, ... American journal of hematology 88 (8), 642-646, 2013 | 91 | 2013 |
| Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX cohort study V Naranbhai, CA Pernat, A Gavralidis, KJ St Denis, EC Lam, LM Spring, ... Journal of Clinical Oncology 40 (1), 12-23, 2022 | 86 | 2022 |
| Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short-and long-term clinical outcomes: a large, retrospective … M Stahl, RM Shallis, W Wei, P Montesinos, E Lengline, J Neukirchen, ... Leukemia 34 (12), 3149-3160, 2020 | 86 | 2020 |
| Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies AM Brunner, HT Kim, E Coughlin, EP Alyea III, P Armand, KK Ballen, ... Biology of Blood and Marrow Transplantation 19 (9), 1374-1380, 2013 | 86 | 2013 |
